Hemorrhoid Disease: A Review on Treatment, Clinical Research and Patent Data.

Q3 Pharmacology, Toxicology and Pharmaceutics

Infectious disorders drug targets Pub Date : 2023-01-01 DOI:10.2174/1871526523666230427115436

Vishakha Devi, Geeta Deswal, Rameshwar Dass, Bhawna Chopra, Priyanka Kriplani, Ajmer Singh Grewal, Ashwani K Dhingra

{"title":"Hemorrhoid Disease: A Review on Treatment, Clinical Research and Patent Data.","authors":"Vishakha Devi, Geeta Deswal, Rameshwar Dass, Bhawna Chopra, Priyanka Kriplani, Ajmer Singh Grewal, Ashwani K Dhingra","doi":"10.2174/1871526523666230427115436","DOIUrl":null,"url":null,"abstract":"Background: Hemorrhoid disease (HD) is an anal-rectal ailment that is commonly painful or may be painless and causes rectal bleeding with or without prolapsing anal tissue. It is generally associated with bleeding, prolapse, pruritus, and discomfort, which results in a diminished quality of life and well-being.Objective: To highlight the recent developments in terms of safety, clinical efficacy, and marketed formulation for the effective management of hemorrhoids.Method: Reported literature available on Scopus, PubMed, Science Direct, Clinicaltrails.gov, and from many reputed foundations has been studied to summarize the recent development and clinical studies for the management of hemorrhoids.Results and conclusion: The high incidence of hemorrhoids obliges the development of new molecules; therefore, safe and efficient drugs to confer protection against hemorrhoids are urgently needed. This review article mainly focuses on the newer molecules to overcome hemorrhoids and also emphasizes various studies carried out in the past.","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 6","pages":"e270423216271"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526523666230427115436","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hemorrhoid disease (HD) is an anal-rectal ailment that is commonly painful or may be painless and causes rectal bleeding with or without prolapsing anal tissue. It is generally associated with bleeding, prolapse, pruritus, and discomfort, which results in a diminished quality of life and well-being.

Objective: To highlight the recent developments in terms of safety, clinical efficacy, and marketed formulation for the effective management of hemorrhoids.

Method: Reported literature available on Scopus, PubMed, Science Direct, Clinicaltrails.gov, and from many reputed foundations has been studied to summarize the recent development and clinical studies for the management of hemorrhoids.

Results and conclusion: The high incidence of hemorrhoids obliges the development of new molecules; therefore, safe and efficient drugs to confer protection against hemorrhoids are urgently needed. This review article mainly focuses on the newer molecules to overcome hemorrhoids and also emphasizes various studies carried out in the past.

查看原文本刊更多论文

痔疮病:治疗、临床研究及专利资料综述。

背景:痔疮病(HD)是一种肛门直肠疾病，通常疼痛或可能无痛，引起直肠出血伴或不伴肛门组织脱垂。它通常与出血、脱垂、瘙痒和不适有关，导致生活质量下降和健康状况下降。目的:强调在安全性、临床疗效和市场配方方面的最新进展，以有效地治疗痔疮。方法:通过查阅Scopus、PubMed、Science Direct、Clinicaltrails.gov等知名基金会的相关文献，总结痔疮治疗的最新进展和临床研究。结果与结论:痔疮的高发病率促使新分子的开发;因此，迫切需要安全有效的药物来预防痔疮。本文主要综述了治疗痔疮的新分子，并着重介绍了以往开展的各种研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.10

自引率

0.00%

发文量

123

期刊介绍： Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.